-
Something wrong with this record ?
Hydrophobic deep eutectic solvent (HDES) as oil phase in lipid-based drug formulations
S. Panbachi, J. Beranek, M. Kuentz
Language English Country Netherlands
Document type Journal Article
- MeSH
- Chemistry, Pharmaceutical methods MeSH
- Hydrophobic and Hydrophilic Interactions * MeSH
- Lauric Acids chemistry MeSH
- Lipids * chemistry MeSH
- Oils chemistry MeSH
- Polysorbates chemistry MeSH
- Surface-Active Agents * chemistry MeSH
- Drug Compounding * methods MeSH
- Solvents * chemistry MeSH
- Solubility * MeSH
- Molecular Dynamics Simulation * MeSH
- Sulfonamides chemistry administration & dosage MeSH
- Drug Liberation * MeSH
- Publication type
- Journal Article MeSH
There is increasing pharmaceutical interest in deep eutectic solvents not only as a green alternative to organic solvents in drug manufacturing, but also as liquid formulation for drug delivery. The present work introduces a hydrophobic deep eutectic solvent (HDES) to the field of lipid-based formulations (LBF). Phase behavior of a mixture with 2:1 M ratio of decanoic- to dodecanoic acid was studied experimentally and described by thermodynamic modelling. Venetoclax was selected as a hydrophobic model drug and studied by atomistic molecular dynamics simulations of the mixtures. As a result, valuable molecular insights were gained into the interaction networks between the different components. Moreover, experimentally the HDES showed greatly enhanced drug solubilization compared to conventional glyceride-based vehicles, but aqueous dispersion behavior was limited. Hence surfactants were studied for their ability to improve aqueous dispersion and addition of Tween 80 resulted in lowest droplet sizes and high in vitro drug release. In conclusion, the combination of HDES with surfactant(s) provides a novel LBF with high pharmaceutical potential. However, the components must be finely balanced to keep the integrity of the solubilizing HDES, while enabling sufficient dispersion and drug release.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24019331
- 003
- CZ-PrNML
- 005
- 20241024111519.0
- 007
- ta
- 008
- 241015e20240702ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ijpharm.2024.124418 $2 doi
- 035 __
- $a (PubMed)38964488
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Panbachi, Shaida $u Zentiva, k.s., U Kabelovny 130 102 00, Praha 10, Czech Republic; University of Basel, Department of Pharmaceutical Sciences, Klingelbergstrasse 50 4056, Basel, Switzerland; University of Applied Sciences and Arts Northwest. Switzerland, School of Life Sciences, Institute of Pharma Technology, Hofackerstr. 30 CH- 4132, Muttenz, Switzerland
- 245 10
- $a Hydrophobic deep eutectic solvent (HDES) as oil phase in lipid-based drug formulations / $c S. Panbachi, J. Beranek, M. Kuentz
- 520 9_
- $a There is increasing pharmaceutical interest in deep eutectic solvents not only as a green alternative to organic solvents in drug manufacturing, but also as liquid formulation for drug delivery. The present work introduces a hydrophobic deep eutectic solvent (HDES) to the field of lipid-based formulations (LBF). Phase behavior of a mixture with 2:1 M ratio of decanoic- to dodecanoic acid was studied experimentally and described by thermodynamic modelling. Venetoclax was selected as a hydrophobic model drug and studied by atomistic molecular dynamics simulations of the mixtures. As a result, valuable molecular insights were gained into the interaction networks between the different components. Moreover, experimentally the HDES showed greatly enhanced drug solubilization compared to conventional glyceride-based vehicles, but aqueous dispersion behavior was limited. Hence surfactants were studied for their ability to improve aqueous dispersion and addition of Tween 80 resulted in lowest droplet sizes and high in vitro drug release. In conclusion, the combination of HDES with surfactant(s) provides a novel LBF with high pharmaceutical potential. However, the components must be finely balanced to keep the integrity of the solubilizing HDES, while enabling sufficient dispersion and drug release.
- 650 12
- $a hydrofobní a hydrofilní interakce $7 D057927
- 650 12
- $a rozpouštědla $x chemie $7 D012997
- 650 12
- $a povrchově aktivní látky $x chemie $7 D013501
- 650 12
- $a rozpustnost $7 D012995
- 650 12
- $a uvolňování léčiv $7 D065546
- 650 12
- $a lipidy $x chemie $7 D008055
- 650 12
- $a simulace molekulární dynamiky $7 D056004
- 650 12
- $a příprava léků $x metody $7 D004339
- 650 _2
- $a polysorbáty $x chemie $7 D011136
- 650 _2
- $a kyseliny laurové $x chemie $7 D007850
- 650 _2
- $a farmaceutická chemie $x metody $7 D002626
- 650 _2
- $a sulfonamidy $x chemie $x aplikace a dávkování $7 D013449
- 650 _2
- $a oleje $x chemie $7 D009821
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Beranek, Josef $u Zentiva, k.s., U Kabelovny 130 102 00, Praha 10, Czech Republic
- 700 1_
- $a Kuentz, Martin $u University of Applied Sciences and Arts Northwest. Switzerland, School of Life Sciences, Institute of Pharma Technology, Hofackerstr. 30 CH- 4132, Muttenz, Switzerland. Electronic address: martin.kuentz@fhnw.ch
- 773 0_
- $w MED00002359 $t International journal of pharmaceutics $x 1873-3476 $g Roč. 661 (20240702), s. 124418
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38964488 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111513 $b ABA008
- 999 __
- $a ok $b bmc $g 2201896 $s 1231304
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 661 $c - $d 124418 $e 20240702 $i 1873-3476 $m International journal of pharmaceutics $n Int J Pharm $x MED00002359
- LZP __
- $a Pubmed-20241015